Anti-human Neuropilin-1 b1b2 [clone 7E8; mAB3]

Monoclonal antibody raised against human NRP-1 b1b2 domain, clone 7E8 (mAB3 in studies published in Science). Complete blockade of CendR peptides to b1 domain of NRP-1.

Contributors

Institute
University of Tartu
SKU: 160471
Product description: Monoclonal antibody raised against human NRP-1 b1b2 domain, clone 7E8 (mAB3 in studies published in Science). Complete blockade of CendR peptides to b1 domain of NRP-1. In recent years the relevance of CendR pathway for cellular uptake of biological nanoparticles – viruses – has been demonstrated in several independent studies. A direct role of Neuropilin (NRP) in virus entry has been demonstrated for three viruses, the retrovirus Human T-cell lymphotropic virus type 1 (HTLV-1) and the herpes viruses EBV and CMV5-8. In the case of CMV, NRP-2 acts as a receptor only for specific cell types, while in fibroblasts the virus uses a different molecule for entry. Viruses that display CendR peptides on their surface are expected to bind a specific CendR binding pocket on the extracellular domain of NRP. Ample evidence obtained with synthetic and phage-displayed CendR peptides shows that they bind to conserved binding pocket in b1 domain of NRP-1. The inventors have developed a monoclonal antibody that specifically interacts with the CendR binding pocket of the b1 domain of Neuropilin-1 and blocks binding of CendR peptides. This monoclonal antibody has potential applications in the research of SARS-CoV2 in that the antibody is capable to reduce/block the internalisation of SARS-CoV2 into cells, thus to stop viral replication.
Alternate name: 7E8, mAb3 (mAB3 in studies published in Science)
Conjugation: Unconjugated
Isotype: IgG1 kappa
Immunogen: Human wild-type Neuropilin-1 CendR b1b2 region
Myeloma used: P3X63Ag8.653
Cat. #: 160471
Unit size: 100 ug
Application: IHC ; IF ; WB
Target: human Neuropillin-1 b1b2 domain
Reactivity: Human
Host: Mouse
Class: Monoclonal
Target background: Monoclonal antibody raised against human NRP-1 b1b2 domain, clone 7E8 (mAB3 in studies published in Science). Complete blockade of CendR peptides to b1 domain of NRP-1. In recent years the relevance of CendR pathway for cellular uptake of biological nanoparticles – viruses – has been demonstrated in several independent studies. A direct role of Neuropilin (NRP) in virus entry has been demonstrated for three viruses, the retrovirus Human T-cell lymphotropic virus type 1 (HTLV-1) and the herpes viruses EBV and CMV5-8. In the case of CMV, NRP-2 acts as a receptor only for specific cell types, while in fibroblasts the virus uses a different molecule for entry. Viruses that display CendR peptides on their surface are expected to bind a specific CendR binding pocket on the extracellular domain of NRP. Ample evidence obtained with synthetic and phage-displayed CendR peptides shows that they bind to conserved binding pocket in b1 domain of NRP-1. The inventors have developed a monoclonal antibody that specifically interacts with the CendR binding pocket of the b1 domain of Neuropilin-1 and blocks binding of CendR peptides. This monoclonal antibody has potential applications in the research of SARS-CoV2 in that the antibody is capable to reduce/block the internalisation of SARS-CoV2 into cells, thus to stop viral replication.
Format: Liquid
Concentration: 1mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Canturi-Castelvetri et al,. 2020doi:10.1101/2020.06.07.137802

Cantuti-Castelvetri et al. 2020. Science. 370(6518):856-860. PMID: 33082293.

Images

View Gallery

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.